Kailera Therapeutics Inc. disclosed the pricing of its initial public offering at $16.00 per share for 39,062,500 shares of common stock, indicating expected gross proceeds of $625.0 million before accounting for underwriting discounts and offering expenses. The company, which identifies itself as an advanced clinical-stage biotechnology firm focused on obesity treatments, is based in Waltham, Massachusetts.
The planned Nasdaq listing is scheduled to commence trading on the Nasdaq Global Select Market on April 17, 2026. Kailera has stated that the offering is expected to close on April 20, 2026, though that closing will be subject to customary closing conditions.
Under terms outlined in the company filing, the underwriters have a 30-day option to purchase up to an additional 5,859,375 shares at the IPO price less underwriting discounts and commissions. All shares in the offering are being sold by Kailera, according to the company statement.
The Securities and Exchange Commission declared effective the company’s registration statement on Form S-1 (File No. 333-294690) for this offering on April 16, 2026. In its public filings, Kailera presents itself as an advanced clinical-stage biotechnology company concentrating on obesity treatments.
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are named as joint book-running managers for the transaction. William Blair is listed as the lead manager for the offering.
The company’s disclosure notes that the stated $625.0 million figure represents gross proceeds, which does not account for underwriting discounts and offering expenses that will reduce net proceeds. The inclusion of an underwriters’ option to buy additional shares means the total number of shares that may ultimately be sold in the offering could increase within the 30-day option period.
Context and next steps
Kailera will proceed toward listing on the Nasdaq Global Select Market as scheduled on April 17, 2026, pending the completion of the offering on or about April 20, 2026, and the satisfaction of customary closing conditions. The SEC’s declaration of effectiveness on April 16, 2026, clears the registration statement filed on Form S-1 (File No. 333-294690) for the offering.
The offering structure identifies the selling party as Kailera and names the underwriting syndicate and lead manager responsible for book-running and distribution. The 30-day option granted to underwriters provides flexibility to increase the aggregate shares sold at the IPO price less applicable underwriting discounts and commissions.